<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01892436</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457F2306E1</org_study_id>
    <secondary_id>2013-001241-13</secondary_id>
    <nct_id>NCT01892436</nct_id>
  </id_info>
  <brief_title>Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis</brief_title>
  <acronym>FUTURE 1 ext</acronym>
  <official_title>A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed as a 3-year extension to the phase III core study CAIN457F2306. It
      aimed to provide continuous treatment with secukinumab in pre-filled syringes (PFS) for
      subjects who completed the core study CAIN457F2306, to obtain further long term efficacy,
      safety and tolerability information in subjects with active psoriatic arthritis receiving
      secukinumab every 4 weeks. At Week 104 of the study CAIN457F2306, eligible subjects completed
      the assessments associated with the core study visit and subsequently continued in this
      extension study on the same dose that they were receiving during the core study. The regular
      assessments of disease activity ensure that subjects who are experienced worsening of disease
      in any of the treatment groups could exit the study upon their own wish or based on the
      advice of the investigator at any time.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 30, 2013</start_date>
  <completion_date type="Actual">January 11, 2018</completion_date>
  <primary_completion_date type="Actual">January 11, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Subject Who Reached (American College of Rheumatology Score of 20) ACR20</measure>
    <time_frame>weeks 116, 128, 140, 156, 180, 208, 232 and 260</time_frame>
    <description>Proportion of subjects with a positive clinical response to treatment (individual improvement) in disease activity according to ACR20 criteria if he/she has at least 20% improvement in 1. Tender 68-joint count 2. Swollen 66-joint count and 3. At least 3 of the following 5 measures:
Patient's assessment of Psoriatic Arthritis (PsA) pain
Patient's global assessment of disease activity
Physician's global assessment of disease activity
Subject self-assessed disability (Health-Assessment Questionnaire [HAQ-DI] score)
Acute phase reactant (hsCRP or ESR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Subjects Who Reached ACR50</measure>
    <time_frame>weeks 116, 128, 140, 156, 180, 208, 232 and 260</time_frame>
    <description>Proportion of subjects that have a positive clinical response to treatment (individual improvement) in disease activity according to ACR50 criteria if he/she has at least 50% improvement in 1. Tender 68-joint count 2. Swollen 66-joint count and 3. At least 3 of the following 5 measures:
Patient's assessment of PsA pain
Patient's global assessment of disease activity
Physician's global assessment of disease activity
Subject self-assessed disability (Health-Assessment Questionnaire [HAQ-DI] score)
Acute phase reactant (hsCRP or ESR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Subjects Who Reached ACR70</measure>
    <time_frame>weeks 116, 128, 140, 156, 180, 208, 232 and 260</time_frame>
    <description>Proportion of subjects that have a positive clinical response to treatment (individual improvement) in disease activity according to ACR70 criteria if he/she has at least 70% improvement in 1. Tender 68-joint count 2. Swollen 66-joint count and 3. At least 3 of the following 5 measures:- Patient's assessment of PsA pain
Patient's global assessment of disease activity
Physician's global assessment of disease activity
Subject self-assessed disability (Health-Assessment Questionnaire [HAQ-DI] score)
Acute phase reactant (hsCRP or ESR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)</measure>
    <time_frame>weeks 116, 128, 140, 156, 180, 208, 232 and 260</time_frame>
    <description>Changes from baseline in score of the disability assessment component of the HAQ (Health Assessment Questionnaire - Disability Index). The HAQ-DI, assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities.
Health Assessment Questionnaire - Disability Index (HAQ-DI) ranges from 0 (no disability) to 3 (very severe disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Clinically Important Difference (MCID) in Health Assessment Questionnaire Disability Index (HAQ-DI)</measure>
    <time_frame>weeks 116, 128, 140, 156, 180, 208, 232 and 260</time_frame>
    <description>Percentage of subjects with improvements from baseline in HAQ-DI meeting or exceeding minimal clinically important difference (MCID=0.3). The HAQ-DI, assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Activity Score-CRP (DAS28)</measure>
    <time_frame>weeks 116, 128, 140, 156, 180, 208, 232 and 260</time_frame>
    <description>Changes in DAS28 (utilizing hsCRP) from baseline up to Month 60. The DAS28 is a measure of disease activity in PsA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient's Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission. This measure represents change in scores - not the actual scores.
DAS28 is a combined measure of disease activity based on the following formula:
DAS28-CRP = 0.56*TJC28^0.5 + 0.28*SJC28^0.5 + 0.36*ln(CRP+1) + 0.014*PGA + 0.96 The greater the score is, the more the disease activity exists. Remission is defined as DAS28-CRP &lt; 2.6 Low disease activity is defined as DAS28-CRP &lt; 3.2 The minimum value can be 0.96 (not applicable in our study due to the inclusion/exclusion criteria regarding tender, swollen joints). There is no maximum expected value for this score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieving Low Disease Activity</measure>
    <time_frame>weeks 116, 128, 140, 156, 180, 208, 232 and 260</time_frame>
    <description>Percentage of subjects achieving low disease activity (DAS28 â‰¤ 3.2). The DAS28 is a measure of disease activity in PsA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient's Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieving Disease Remission (DAS28&lt;2.6)</measure>
    <time_frame>weeks 116, 128, 140, 156, 180, 208, 232 and 260</time_frame>
    <description>Percentage of subjects achieving disease remission (DAS28&lt;2.6). The DAS28 is a measure of disease activity in PsA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient's Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">460</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Secukinumab 75mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects continued to receive secukinumab 75mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Secukinumab 150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects continued to receive secukinumab 150mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 300 mg as judged appropriate by the investigator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - AIN457A 75mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 0.5 mL solution solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 75mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - AIN457 150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 1 mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 150 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Secukinumab</intervention_name>
    <description>Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a &quot;messenger&quot; protein in the body) called Interleukin 17 (IL-17).</description>
    <arm_group_label>Placebo - AIN457 150mg</arm_group_label>
    <arm_group_label>Placebo - AIN457A 75mg</arm_group_label>
    <arm_group_label>Secukinumab 150mg</arm_group_label>
    <arm_group_label>Secukinumab 75mg</arm_group_label>
    <other_name>AIN457</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo - AIN457 150mg</arm_group_label>
    <arm_group_label>Placebo - AIN457A 75mg</arm_group_label>
    <other_name>Placebo - AIN457A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Subjects must be able to understand and communicate with the investigator and comply
             with the requirements of the study and must give a written, signed and dated informed
             consent before any study assessment is performed

          -  Subjects must have participated in core study CAIN457F2306, and must have completed
             the entire treatment period

          -  Subjects must be deemed by the investigator to benefit from continued secukinumab
             therapy

        Exclusion criteria

          -  Any subject taking other concomitant biologic immunomodulating agent(s) except
             secukinumab

          -  Any subject who is deemed not to be benefiting from the study treatment based upon
             lack of improvement or worsening of their symptoms

          -  Pregnant or nursing (lactating) women

          -  Women of child-bearing potential, unless they are using effective methods of
             contraception during the entire study or longer if required by locally approved
             prescribing information (e.g., 20 weeks in EU)

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207-5710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paradise Valley</city>
        <state>Arizona</state>
        <zip>85253</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Eagan</city>
        <state>Minnesota</state>
        <zip>55121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freehold</city>
        <state>New Jersey</state>
        <zip>07728</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Benbrook</city>
        <state>Texas</state>
        <zip>76126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>League City</city>
        <state>Texas</state>
        <zip>77573</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000CFJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1417EYG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <zip>C1419AHN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5016KEH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>CÃ³rdoba</city>
        <zip>X5000EDC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maroochydore</city>
        <state>Queensland</state>
        <zip>4558</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malvern East</city>
        <state>Victoria</state>
        <zip>3145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04023-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04266 010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevlievo</city>
        <state>Gabrovo</state>
        <zip>5400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1A 5E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1C 5B8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 3R7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trois-Rivieres</city>
        <state>Quebec</state>
        <zip>G8Z 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruntal</city>
        <state>Czech Republic</state>
        <zip>792 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uherske Hradiste</city>
        <state>Czech Republic</state>
        <zip>686 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zlin</city>
        <state>Czech Republic</state>
        <zip>760 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aachen</city>
        <zip>52064</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91056</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gommern</city>
        <zip>39245</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22415</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hildesheim</city>
        <zip>31134</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>NÃ¼rnberg</city>
        <zip>90429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ratingen</city>
        <zip>40878</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zerbst</city>
        <zip>39261</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ashkelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Haifa</city>
        <zip>3339419</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prato</city>
        <state>PO</state>
        <zip>59100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Siena</city>
        <state>SI</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Verona</city>
        <state>VR</state>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lipa City</city>
        <state>Batangas</state>
        <zip>4217</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dasmarinas</city>
        <state>Cavite</state>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manila</city>
        <state>Metro Manila</state>
        <zip>1003</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Las Pinas</city>
        <zip>1740</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manila</city>
        <zip>1003</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manila</city>
        <zip>1008</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1102</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1118</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-351</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-341</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620109</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kemerovo</city>
        <zip>650029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>190068</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>529889</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lucenec</city>
        <zip>984 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Khon Kaen</city>
        <state>THA</state>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leytonstone</city>
        <state>London</state>
        <zip>E11 1NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cannock</city>
        <state>Staffordshire</state>
        <zip>WS11 2XY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bradford</city>
        <state>West Yorkshire</state>
        <zip>BD5 0NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G31 2ER</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>July 1, 2013</study_first_submitted>
  <study_first_submitted_qc>July 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2013</study_first_posted>
  <results_first_submitted>January 10, 2019</results_first_submitted>
  <results_first_submitted_qc>May 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 12, 2019</results_first_posted>
  <last_update_submitted>May 20, 2019</last_update_submitted>
  <last_update_submitted_qc>May 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Extension study, psoriatic arthritis, pre-filled syringe</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 22, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT01892436/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT01892436/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The extension FAS (N=457) comprised all patients enrolled in the extension with at least 1 post baseline efficacy assessment during the extension study. 3 patients signed the ICF but had no efficacy assessments during the extension study and were not included in extension FAS.</recruitment_details>
      <pre_assignment_details>Of the 457 patients in the extension FAS, 380 (83.2%) completed 260 weeks of treatment (84.4% in the secukinumab 10 mg/kg-75 mg group, 82.0% in the secukinumab 10 mg/kg-150 mg group, 85.1% in the placebo-secukinumab 75 mg group and 81.3% in the placebo-secukinumab 150 mg group)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Secukinumab 75mg</title>
          <description>Subjects continued to receive secukinumab 75mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator</description>
        </group>
        <group group_id="P2">
          <title>Secukinumab 150mg</title>
          <description>Subjects continued to receive secukinumab 150mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 300 mg as judged appropriate by the investigator</description>
        </group>
        <group group_id="P3">
          <title>Placebo - AIN457A 75mg</title>
          <description>Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 1.0 mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 75mg. Participants also received secukinumab 75mg from week 16/24. Patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator</description>
        </group>
        <group group_id="P4">
          <title>Placebo - AIN457 150mg</title>
          <description>Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 0.5mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 150 mg. Participants also received secukinumab 150 mg from week 16/24. patients may have been escalated to 300mg or 300 mg as judged appropriate by investigator</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="161"/>
                <participants group_id="P3" count="74"/>
                <participants group_id="P4" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
                <participants group_id="P2" count="132"/>
                <participants group_id="P3" count="63"/>
                <participants group_id="P4" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technical problems</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non-compliance with treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Extension Full Analysis Set (extension FAS) is comprised all patients enrolled in the extension study who had at least one post baseline assessment of efficacy during the extension period. Patients were analyzed according to the treatment they were assigned.</population>
      <group_list>
        <group group_id="B1">
          <title>Secukinumab 75mg</title>
          <description>Subjects initially continued to receive secukinumab 75mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator</description>
        </group>
        <group group_id="B2">
          <title>Secukinumab 150mg</title>
          <description>Subjects continued to receive secukinumab 150mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 300 mg as judged appropriate by the investigator</description>
        </group>
        <group group_id="B3">
          <title>Placebo - AIN457A 75mg</title>
          <description>Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 1.0 mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 75mg. Participants also received secukinumab 75mg from week 16/24. Patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator</description>
        </group>
        <group group_id="B4">
          <title>Placebo - AIN457 150mg</title>
          <description>Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 0.5mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 150 mg. Participants also received secukinumab 150 mg from week 16/24. patients may have been escalated to 300mg or 300 mg as judged appropriate by investigator</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="147"/>
            <count group_id="B2" value="161"/>
            <count group_id="B3" value="74"/>
            <count group_id="B4" value="75"/>
            <count group_id="B5" value="457"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Age groups are reported cumulatively so categories are not mutually exclusive.</description>
          <units>Count of Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="71"/>
                    <measurement group_id="B5" value="420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="242"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Count of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="58"/>
                    <measurement group_id="B5" value="357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Subject Who Reached (American College of Rheumatology Score of 20) ACR20</title>
        <description>Proportion of subjects with a positive clinical response to treatment (individual improvement) in disease activity according to ACR20 criteria if he/she has at least 20% improvement in 1. Tender 68-joint count 2. Swollen 66-joint count and 3. At least 3 of the following 5 measures:
Patient's assessment of Psoriatic Arthritis (PsA) pain
Patient's global assessment of disease activity
Physician's global assessment of disease activity
Subject self-assessed disability (Health-Assessment Questionnaire [HAQ-DI] score)
Acute phase reactant (hsCRP or ESR)</description>
        <time_frame>weeks 116, 128, 140, 156, 180, 208, 232 and 260</time_frame>
        <population>Extension Full Analysis Set (extension FAS) is comprised all patients enrolled in the extension study who had at least one post baseline assessment of efficacy during the extension period. Patients were analyzed according to the treatment they were assigned.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 75mg</title>
            <description>Subjects initially continued to receive secukinumab 75mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150mg</title>
            <description>Subjects continued to receive secukinumab 150mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 300 mg as judged appropriate by the investigator</description>
          </group>
          <group group_id="O3">
            <title>Placebo - AIN457A 75mg</title>
            <description>Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 1.0 mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 75mg. Participants also received secukinumab 75mg from week 16/24. Patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator</description>
          </group>
          <group group_id="O4">
            <title>Placebo - AIN457 150mg</title>
            <description>Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 0.5mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 150 mg. Participants also received secukinumab 150 mg from week 16/24. patients may have been escalated to 300mg or 300 mg as judged appropriate by investigator</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subject Who Reached (American College of Rheumatology Score of 20) ACR20</title>
          <description>Proportion of subjects with a positive clinical response to treatment (individual improvement) in disease activity according to ACR20 criteria if he/she has at least 20% improvement in 1. Tender 68-joint count 2. Swollen 66-joint count and 3. At least 3 of the following 5 measures:
Patient's assessment of Psoriatic Arthritis (PsA) pain
Patient's global assessment of disease activity
Physician's global assessment of disease activity
Subject self-assessed disability (Health-Assessment Questionnaire [HAQ-DI] score)
Acute phase reactant (hsCRP or ESR)</description>
          <population>Extension Full Analysis Set (extension FAS) is comprised all patients enrolled in the extension study who had at least one post baseline assessment of efficacy during the extension period. Patients were analyzed according to the treatment they were assigned.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="161"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 116</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.3" lower_limit="63.1" upper_limit="78.4"/>
                    <measurement group_id="O2" value="73.9" lower_limit="66.0" upper_limit="80.5"/>
                    <measurement group_id="O3" value="73.2" lower_limit="61.2" upper_limit="82.7"/>
                    <measurement group_id="O4" value="73.6" lower_limit="61.7" upper_limit="83.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 128</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.7" lower_limit="61.4" upper_limit="77.0"/>
                    <measurement group_id="O2" value="72.9" lower_limit="65.1" upper_limit="79.6"/>
                    <measurement group_id="O3" value="76.8" lower_limit="64.8" upper_limit="85.8"/>
                    <measurement group_id="O4" value="74.6" lower_limit="62.7" upper_limit="83.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 140</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.8" lower_limit="61.3" upper_limit="77.1"/>
                    <measurement group_id="O2" value="71.1" lower_limit="63.1" upper_limit="78.0"/>
                    <measurement group_id="O3" value="79.2" lower_limit="67.7" upper_limit="87.5"/>
                    <measurement group_id="O4" value="69.4" lower_limit="57.3" upper_limit="79.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.3" lower_limit="55.8" upper_limit="72.0"/>
                    <measurement group_id="O2" value="76.1" lower_limit="68.5" upper_limit="82.4"/>
                    <measurement group_id="O3" value="75.3" lower_limit="63.6" upper_limit="84.4"/>
                    <measurement group_id="O4" value="67.6" lower_limit="55.6" upper_limit="77.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.0" lower_limit="64.6" upper_limit="80.0"/>
                    <measurement group_id="O2" value="72.5" lower_limit="64.1" upper_limit="79.6"/>
                    <measurement group_id="O3" value="74.6" lower_limit="62.3" upper_limit="84.1"/>
                    <measurement group_id="O4" value="67.7" lower_limit="54.8" upper_limit="78.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 208</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.8" lower_limit="64.4" upper_limit="79.9"/>
                    <measurement group_id="O2" value="66.9" lower_limit="58.5" upper_limit="74.3"/>
                    <measurement group_id="O3" value="75.0" lower_limit="62.8" upper_limit="84.4"/>
                    <measurement group_id="O4" value="68.2" lower_limit="55.4" upper_limit="78.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 232</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.5" lower_limit="71.3" upper_limit="86.0"/>
                    <measurement group_id="O2" value="69.5" lower_limit="60.7" upper_limit="77.0"/>
                    <measurement group_id="O3" value="83.3" lower_limit="71.7" upper_limit="91.0"/>
                    <measurement group_id="O4" value="80.3" lower_limit="67.8" upper_limit="89.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 260</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.2" lower_limit="68.7" upper_limit="83.9"/>
                    <measurement group_id="O2" value="67.9" lower_limit="59.1" upper_limit="75.7"/>
                    <measurement group_id="O3" value="78.8" lower_limit="66.7" upper_limit="87.5"/>
                    <measurement group_id="O4" value="77.4" lower_limit="64.7" upper_limit="86.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Subjects Who Reached ACR50</title>
        <description>Proportion of subjects that have a positive clinical response to treatment (individual improvement) in disease activity according to ACR50 criteria if he/she has at least 50% improvement in 1. Tender 68-joint count 2. Swollen 66-joint count and 3. At least 3 of the following 5 measures:
Patient's assessment of PsA pain
Patient's global assessment of disease activity
Physician's global assessment of disease activity
Subject self-assessed disability (Health-Assessment Questionnaire [HAQ-DI] score)
Acute phase reactant (hsCRP or ESR)</description>
        <time_frame>weeks 116, 128, 140, 156, 180, 208, 232 and 260</time_frame>
        <population>Extension FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 75mg</title>
            <description>Subjects initially continued to receive secukinumab 75mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150mg</title>
            <description>Subjects continued to receive secukinumab 150mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 300 mg as judged appropriate by the investigator</description>
          </group>
          <group group_id="O3">
            <title>Placebo - AIN457A 75mg</title>
            <description>Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 1.0 mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 75mg. Participants also received secukinumab 75mg from week 16/24. Patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator</description>
          </group>
          <group group_id="O4">
            <title>Placebo - AIN457 150mg</title>
            <description>Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 0.5mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 150 mg. Participants also received secukinumab 150 mg from week 16/24. patients may have been escalated to 300mg or 300 mg as judged appropriate by investigator</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Who Reached ACR50</title>
          <description>Proportion of subjects that have a positive clinical response to treatment (individual improvement) in disease activity according to ACR50 criteria if he/she has at least 50% improvement in 1. Tender 68-joint count 2. Swollen 66-joint count and 3. At least 3 of the following 5 measures:
Patient's assessment of PsA pain
Patient's global assessment of disease activity
Physician's global assessment of disease activity
Subject self-assessed disability (Health-Assessment Questionnaire [HAQ-DI] score)
Acute phase reactant (hsCRP or ESR)</description>
          <population>Extension FAS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="161"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 116</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.4" lower_limit="35.2" upper_limit="51.9"/>
                    <measurement group_id="O2" value="51.0" lower_limit="42.8" upper_limit="59.1"/>
                    <measurement group_id="O3" value="49.3" lower_limit="37.3" upper_limit="61.3"/>
                    <measurement group_id="O4" value="47.2" lower_limit="35.5" upper_limit="59.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 128</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.7" lower_limit="35.4" upper_limit="52.2"/>
                    <measurement group_id="O2" value="52.9" lower_limit="44.8" upper_limit="60.9"/>
                    <measurement group_id="O3" value="56.5" lower_limit="44.1" upper_limit="68.2"/>
                    <measurement group_id="O4" value="53.5" lower_limit="41.4" upper_limit="65.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 140</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7" lower_limit="33.5" upper_limit="50.4"/>
                    <measurement group_id="O2" value="48.7" lower_limit="40.5" upper_limit="56.9"/>
                    <measurement group_id="O3" value="51.4" lower_limit="39.4" upper_limit="63.2"/>
                    <measurement group_id="O4" value="44.4" lower_limit="32.9" upper_limit="56.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2" lower_limit="31.2" upper_limit="47.7"/>
                    <measurement group_id="O2" value="56.1" lower_limit="47.9" upper_limit="64.0"/>
                    <measurement group_id="O3" value="52.1" lower_limit="40.1" upper_limit="63.8"/>
                    <measurement group_id="O4" value="47.3" lower_limit="35.7" upper_limit="59.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.1" lower_limit="34.7" upper_limit="51.8"/>
                    <measurement group_id="O2" value="45.7" lower_limit="37.2" upper_limit="54.3"/>
                    <measurement group_id="O3" value="52.2" lower_limit="39.8" upper_limit="64.4"/>
                    <measurement group_id="O4" value="50.8" lower_limit="38.2" upper_limit="63.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 208</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.9" lower_limit="36.4" upper_limit="53.6"/>
                    <measurement group_id="O2" value="46.9" lower_limit="38.6" upper_limit="55.3"/>
                    <measurement group_id="O3" value="52.9" lower_limit="40.5" upper_limit="65.0"/>
                    <measurement group_id="O4" value="53.0" lower_limit="40.4" upper_limit="65.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 232</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.6" lower_limit="40.7" upper_limit="58.6"/>
                    <measurement group_id="O2" value="53.4" lower_limit="44.5" upper_limit="62.1"/>
                    <measurement group_id="O3" value="53.0" lower_limit="40.4" upper_limit="65.3"/>
                    <measurement group_id="O4" value="50.8" lower_limit="37.8" upper_limit="63.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 260</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.2" lower_limit="42.2" upper_limit="60.1"/>
                    <measurement group_id="O2" value="52.7" lower_limit="43.8" upper_limit="61.4"/>
                    <measurement group_id="O3" value="60.6" lower_limit="47.8" upper_limit="72.2"/>
                    <measurement group_id="O4" value="50.0" lower_limit="37.2" upper_limit="62.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Subjects Who Reached ACR70</title>
        <description>Proportion of subjects that have a positive clinical response to treatment (individual improvement) in disease activity according to ACR70 criteria if he/she has at least 70% improvement in 1. Tender 68-joint count 2. Swollen 66-joint count and 3. At least 3 of the following 5 measures:- Patient's assessment of PsA pain
Patient's global assessment of disease activity
Physician's global assessment of disease activity
Subject self-assessed disability (Health-Assessment Questionnaire [HAQ-DI] score)
Acute phase reactant (hsCRP or ESR)</description>
        <time_frame>weeks 116, 128, 140, 156, 180, 208, 232 and 260</time_frame>
        <population>Extension FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 75mg</title>
            <description>Subjects initially continued to receive secukinumab 75mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150mg</title>
            <description>Subjects continued to receive secukinumab 150mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 300 mg as judged appropriate by the investigator</description>
          </group>
          <group group_id="O3">
            <title>Placebo - AIN457A 75mg</title>
            <description>Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 1.0 mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 75mg. Participants also received secukinumab 75mg from week 16/24. Patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator</description>
          </group>
          <group group_id="O4">
            <title>Placebo - AIN457 150mg</title>
            <description>Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 0.5mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 150 mg. Participants also received secukinumab 150 mg from week 16/24. patients may have been escalated to 300mg or 300 mg as judged appropriate by investigator</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Who Reached ACR70</title>
          <description>Proportion of subjects that have a positive clinical response to treatment (individual improvement) in disease activity according to ACR70 criteria if he/she has at least 70% improvement in 1. Tender 68-joint count 2. Swollen 66-joint count and 3. At least 3 of the following 5 measures:- Patient's assessment of PsA pain
Patient's global assessment of disease activity
Physician's global assessment of disease activity
Subject self-assessed disability (Health-Assessment Questionnaire [HAQ-DI] score)
Acute phase reactant (hsCRP or ESR)</description>
          <population>Extension FAS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="161"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 116</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8" lower_limit="17.2" upper_limit="31.8"/>
                    <measurement group_id="O2" value="30.1" lower_limit="23.1" upper_limit="38.1"/>
                    <measurement group_id="O3" value="28.2" lower_limit="18.4" upper_limit="40.3"/>
                    <measurement group_id="O4" value="29.2" lower_limit="19.3" upper_limit="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 128</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6" lower_limit="18.0" upper_limit="32.7"/>
                    <measurement group_id="O2" value="31.0" lower_limit="23.9" upper_limit="39.0"/>
                    <measurement group_id="O3" value="34.8" lower_limit="24.0" upper_limit="47.3"/>
                    <measurement group_id="O4" value="23.9" lower_limit="14.9" upper_limit="35.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 140</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3" lower_limit="20.3" upper_limit="35.7"/>
                    <measurement group_id="O2" value="28.3" lower_limit="21.4" upper_limit="36.3"/>
                    <measurement group_id="O3" value="33.3" lower_limit="22.9" upper_limit="45.5"/>
                    <measurement group_id="O4" value="27.8" lower_limit="18.2" upper_limit="39.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9" lower_limit="19.1" upper_limit="34.0"/>
                    <measurement group_id="O2" value="32.9" lower_limit="25.7" upper_limit="41.0"/>
                    <measurement group_id="O3" value="26.0" lower_limit="16.8" upper_limit="37.8"/>
                    <measurement group_id="O4" value="27.0" lower_limit="17.7" upper_limit="38.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0" lower_limit="20.0" upper_limit="35.4"/>
                    <measurement group_id="O2" value="31.2" lower_limit="23.7" upper_limit="39.7"/>
                    <measurement group_id="O3" value="31.3" lower_limit="20.9" upper_limit="44.0"/>
                    <measurement group_id="O4" value="27.7" lower_limit="17.7" upper_limit="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 208</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.7" lower_limit="18.8" upper_limit="34.1"/>
                    <measurement group_id="O2" value="31.0" lower_limit="23.8" upper_limit="39.3"/>
                    <measurement group_id="O3" value="32.4" lower_limit="21.8" upper_limit="44.9"/>
                    <measurement group_id="O4" value="28.8" lower_limit="18.6" upper_limit="41.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 232</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.4" lower_limit="27.3" upper_limit="44.5"/>
                    <measurement group_id="O2" value="32.1" lower_limit="24.3" upper_limit="40.9"/>
                    <measurement group_id="O3" value="37.9" lower_limit="26.5" upper_limit="50.7"/>
                    <measurement group_id="O4" value="34.4" lower_limit="23.0" upper_limit="47.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 260</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9" lower_limit="25.9" upper_limit="42.9"/>
                    <measurement group_id="O2" value="37.4" lower_limit="29.2" upper_limit="46.3"/>
                    <measurement group_id="O3" value="37.9" lower_limit="26.5" upper_limit="50.7"/>
                    <measurement group_id="O4" value="33.9" lower_limit="22.6" upper_limit="47.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)</title>
        <description>Changes from baseline in score of the disability assessment component of the HAQ (Health Assessment Questionnaire - Disability Index). The HAQ-DI, assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities.
Health Assessment Questionnaire - Disability Index (HAQ-DI) ranges from 0 (no disability) to 3 (very severe disability)</description>
        <time_frame>weeks 116, 128, 140, 156, 180, 208, 232 and 260</time_frame>
        <population>Extension FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 75mg</title>
            <description>Subjects initially continued to receive secukinumab 75mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150mg</title>
            <description>Subjects continued to receive secukinumab 150mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 300 mg as judged appropriate by the investigator</description>
          </group>
          <group group_id="O3">
            <title>Placebo - AIN457A 75mg</title>
            <description>Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 1.0 mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 75mg. Participants also received secukinumab 75mg from week 16/24. Patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator</description>
          </group>
          <group group_id="O4">
            <title>Placebo - AIN457 150mg</title>
            <description>Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 0.5mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 150 mg. Participants also received secukinumab 150 mg from week 16/24. patients may have been escalated to 300mg or 300 mg as judged appropriate by investigator</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)</title>
          <description>Changes from baseline in score of the disability assessment component of the HAQ (Health Assessment Questionnaire - Disability Index). The HAQ-DI, assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities.
Health Assessment Questionnaire - Disability Index (HAQ-DI) ranges from 0 (no disability) to 3 (very severe disability)</description>
          <population>Extension FAS</population>
          <units>change in scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="161"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 116</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4537" spread="0.60617"/>
                    <measurement group_id="O2" value="-0.4592" spread="0.56155"/>
                    <measurement group_id="O3" value="-0.5642" spread="0.56722"/>
                    <measurement group_id="O4" value="-0.4115" spread="0.66721"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 128</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4171" spread="0.61192"/>
                    <measurement group_id="O2" value="-0.4619" spread="0.55835"/>
                    <measurement group_id="O3" value="-0.5143" spread="0.55599"/>
                    <measurement group_id="O4" value="-0.3750" spread="0.69661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 140</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4448" spread="0.61406"/>
                    <measurement group_id="O2" value="-0.4713" spread="0.58791"/>
                    <measurement group_id="O3" value="-0.4635" spread="0.56037"/>
                    <measurement group_id="O4" value="-0.3507" spread="0.69221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4236" spread="0.61896"/>
                    <measurement group_id="O2" value="-0.4266" spread="0.57491"/>
                    <measurement group_id="O3" value="-0.5068" spread="0.62548"/>
                    <measurement group_id="O4" value="-0.3159" spread="0.73507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4617" spread="0.61472"/>
                    <measurement group_id="O2" value="-0.4305" spread="0.59901"/>
                    <measurement group_id="O3" value="-0.5698" spread="0.65258"/>
                    <measurement group_id="O4" value="-0.3538" spread="0.71246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 208</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4463" spread="0.57130"/>
                    <measurement group_id="O2" value="-0.3857" spread="0.59304"/>
                    <measurement group_id="O3" value="-0.5531" spread="0.62622"/>
                    <measurement group_id="O4" value="-0.3447" spread="0.74745"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 232</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4710" spread="0.60931"/>
                    <measurement group_id="O2" value="-0.4122" spread="0.60461"/>
                    <measurement group_id="O3" value="-0.5777" spread="0.66930"/>
                    <measurement group_id="O4" value="-0.3952" spread="0.72115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 260</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4821" spread="0.61170"/>
                    <measurement group_id="O2" value="-0.4036" spread="0.58334"/>
                    <measurement group_id="O3" value="-0.5038" spread="0.61039"/>
                    <measurement group_id="O4" value="-0.3730" spread="0.71306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimal Clinically Important Difference (MCID) in Health Assessment Questionnaire Disability Index (HAQ-DI)</title>
        <description>Percentage of subjects with improvements from baseline in HAQ-DI meeting or exceeding minimal clinically important difference (MCID=0.3). The HAQ-DI, assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities.</description>
        <time_frame>weeks 116, 128, 140, 156, 180, 208, 232 and 260</time_frame>
        <population>Extension FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 75mg</title>
            <description>Subjects initially continued to receive secukinumab 75mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150mg</title>
            <description>Subjects continued to receive secukinumab 150mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 300 mg as judged appropriate by the investigator</description>
          </group>
          <group group_id="O3">
            <title>Placebo - AIN457A 75mg</title>
            <description>Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 1.0 mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 75mg. Participants also received secukinumab 75mg from week 16/24. Patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator</description>
          </group>
          <group group_id="O4">
            <title>Placebo - AIN457 150mg</title>
            <description>Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 0.5mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 150 mg. Participants also received secukinumab 150 mg from week 16/24. patients may have been escalated to 300mg or 300 mg as judged appropriate by investigator</description>
          </group>
        </group_list>
        <measure>
          <title>Minimal Clinically Important Difference (MCID) in Health Assessment Questionnaire Disability Index (HAQ-DI)</title>
          <description>Percentage of subjects with improvements from baseline in HAQ-DI meeting or exceeding minimal clinically important difference (MCID=0.3). The HAQ-DI, assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities.</description>
          <population>Extension FAS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="161"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 116</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.1" lower_limit="44.6" upper_limit="61.5"/>
                    <measurement group_id="O2" value="52.3" lower_limit="44.1" upper_limit="60.4"/>
                    <measurement group_id="O3" value="63.9" lower_limit="51.7" upper_limit="74.6"/>
                    <measurement group_id="O4" value="50.0" lower_limit="38.1" upper_limit="61.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 128</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.8" lower_limit="44.3" upper_limit="61.2"/>
                    <measurement group_id="O2" value="51.9" lower_limit="43.8" upper_limit="60.0"/>
                    <measurement group_id="O3" value="57.1" lower_limit="44.8" upper_limit="68.7"/>
                    <measurement group_id="O4" value="54.9" lower_limit="42.7" upper_limit="66.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 140</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.4" lower_limit="46.7" upper_limit="63.7"/>
                    <measurement group_id="O2" value="52.3" lower_limit="44.1" upper_limit="60.4"/>
                    <measurement group_id="O3" value="56.9" lower_limit="44.8" upper_limit="68.4"/>
                    <measurement group_id="O4" value="48.6" lower_limit="36.8" upper_limit="60.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.8" lower_limit="44.3" upper_limit="61.1"/>
                    <measurement group_id="O2" value="52.3" lower_limit="44.1" upper_limit="60.3"/>
                    <measurement group_id="O3" value="60.8" lower_limit="48.7" upper_limit="71.7"/>
                    <measurement group_id="O4" value="44.6" lower_limit="33.2" upper_limit="56.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.9" lower_limit="48.2" upper_limit="65.3"/>
                    <measurement group_id="O2" value="51.5" lower_limit="42.8" upper_limit="60.1"/>
                    <measurement group_id="O3" value="61.2" lower_limit="48.5" upper_limit="72.6"/>
                    <measurement group_id="O4" value="47.7" lower_limit="35.3" upper_limit="60.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 208</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3" lower_limit="44.6" upper_limit="61.9"/>
                    <measurement group_id="O2" value="50.0" lower_limit="41.6" upper_limit="58.4"/>
                    <measurement group_id="O3" value="59.4" lower_limit="46.9" upper_limit="70.9"/>
                    <measurement group_id="O4" value="48.5" lower_limit="36.1" upper_limit="61.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 232</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2" lower_limit="46.1" upper_limit="64.0"/>
                    <measurement group_id="O2" value="48.9" lower_limit="40.1" upper_limit="57.7"/>
                    <measurement group_id="O3" value="59.1" lower_limit="46.3" upper_limit="70.8"/>
                    <measurement group_id="O4" value="52.5" lower_limit="39.4" upper_limit="65.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 260</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6" lower_limit="46.5" upper_limit="64.3"/>
                    <measurement group_id="O2" value="48.9" lower_limit="40.1" upper_limit="57.7"/>
                    <measurement group_id="O3" value="59.1" lower_limit="46.3" upper_limit="70.8"/>
                    <measurement group_id="O4" value="53.2" lower_limit="40.2" upper_limit="65.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Activity Score-CRP (DAS28)</title>
        <description>Changes in DAS28 (utilizing hsCRP) from baseline up to Month 60. The DAS28 is a measure of disease activity in PsA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient's Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission. This measure represents change in scores - not the actual scores.
DAS28 is a combined measure of disease activity based on the following formula:
DAS28-CRP = 0.56*TJC28^0.5 + 0.28*SJC28^0.5 + 0.36*ln(CRP+1) + 0.014*PGA + 0.96 The greater the score is, the more the disease activity exists. Remission is defined as DAS28-CRP &lt; 2.6 Low disease activity is defined as DAS28-CRP &lt; 3.2 The minimum value can be 0.96 (not applicable in our study due to the inclusion/exclusion criteria regarding tender, swollen joints). There is no maximum expected value for this score</description>
        <time_frame>weeks 116, 128, 140, 156, 180, 208, 232 and 260</time_frame>
        <population>Extension FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 75mg</title>
            <description>Subjects initially continued to receive secukinumab 75mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150mg</title>
            <description>Subjects continued to receive secukinumab 150mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 300 mg as judged appropriate by the investigator</description>
          </group>
          <group group_id="O3">
            <title>Placebo - AIN457A 75mg</title>
            <description>Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 1.0 mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 75mg. Participants also received secukinumab 75mg from week 16/24. Patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator</description>
          </group>
          <group group_id="O4">
            <title>Placebo - AIN457 150mg</title>
            <description>Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 0.5mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 150 mg. Participants also received secukinumab 150 mg from week 16/24. patients may have been escalated to 300mg or 300 mg as judged appropriate by investigator</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Activity Score-CRP (DAS28)</title>
          <description>Changes in DAS28 (utilizing hsCRP) from baseline up to Month 60. The DAS28 is a measure of disease activity in PsA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient's Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission. This measure represents change in scores - not the actual scores.
DAS28 is a combined measure of disease activity based on the following formula:
DAS28-CRP = 0.56*TJC28^0.5 + 0.28*SJC28^0.5 + 0.36*ln(CRP+1) + 0.014*PGA + 0.96 The greater the score is, the more the disease activity exists. Remission is defined as DAS28-CRP &lt; 2.6 Low disease activity is defined as DAS28-CRP &lt; 3.2 The minimum value can be 0.96 (not applicable in our study due to the inclusion/exclusion criteria regarding tender, swollen joints). There is no maximum expected value for this score</description>
          <population>Extension FAS</population>
          <units>change in scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="161"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 116</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.044" spread="1.3382"/>
                    <measurement group_id="O2" value="-1.904" spread="1.3165"/>
                    <measurement group_id="O3" value="-2.282" spread="1.2732"/>
                    <measurement group_id="O4" value="-1.853" spread="1.2737"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 128</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.013" spread="1.3446"/>
                    <measurement group_id="O2" value="-1.962" spread="1.2900"/>
                    <measurement group_id="O3" value="-2.333" spread="1.2815"/>
                    <measurement group_id="O4" value="-2.031" spread="1.3290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 140</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.074" spread="1.3224"/>
                    <measurement group_id="O2" value="-1.912" spread="1.2246"/>
                    <measurement group_id="O3" value="-2.412" spread="1.3059"/>
                    <measurement group_id="O4" value="-1.830" spread="1.3136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.844" spread="1.4923"/>
                    <measurement group_id="O2" value="-1.942" spread="1.3195"/>
                    <measurement group_id="O3" value="-2.109" spread="1.3188"/>
                    <measurement group_id="O4" value="-1.743" spread="1.3630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.058" spread="1.3760"/>
                    <measurement group_id="O2" value="-1.937" spread="1.2674"/>
                    <measurement group_id="O3" value="-2.327" spread="1.2339"/>
                    <measurement group_id="O4" value="-1.867" spread="1.4590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 208</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.042" spread="1.2907"/>
                    <measurement group_id="O2" value="-1.767" spread="1.4574"/>
                    <measurement group_id="O3" value="-2.344" spread="1.3351"/>
                    <measurement group_id="O4" value="-1.862" spread="1.4708"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 232</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.225" spread="1.2570"/>
                    <measurement group_id="O2" value="-2.046" spread="1.2590"/>
                    <measurement group_id="O3" value="-2.611" spread="1.3247"/>
                    <measurement group_id="O4" value="-2.286" spread="1.2102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 260</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.112" spread="1.2664"/>
                    <measurement group_id="O2" value="-2.074" spread="1.3146"/>
                    <measurement group_id="O3" value="-2.506" spread="1.3774"/>
                    <measurement group_id="O4" value="-2.099" spread="1.2466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Achieving Low Disease Activity</title>
        <description>Percentage of subjects achieving low disease activity (DAS28 â‰¤ 3.2). The DAS28 is a measure of disease activity in PsA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient's Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission</description>
        <time_frame>weeks 116, 128, 140, 156, 180, 208, 232 and 260</time_frame>
        <population>Extension FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 75mg</title>
            <description>Subjects initially continued to receive secukinumab 75mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150mg</title>
            <description>Subjects continued to receive secukinumab 150mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 300 mg as judged appropriate by the investigator</description>
          </group>
          <group group_id="O3">
            <title>Placebo - AIN457A 75mg</title>
            <description>Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 1.0 mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 75mg. Participants also received secukinumab 75mg from week 16/24. Patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator</description>
          </group>
          <group group_id="O4">
            <title>Placebo - AIN457 150mg</title>
            <description>Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 0.5mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 150 mg. Participants also received secukinumab 150 mg from week 16/24. patients may have been escalated to 300mg or 300 mg as judged appropriate by investigator</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving Low Disease Activity</title>
          <description>Percentage of subjects achieving low disease activity (DAS28 â‰¤ 3.2). The DAS28 is a measure of disease activity in PsA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient's Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission</description>
          <population>Extension FAS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="161"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 116</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.3" lower_limit="62.1" upper_limit="77.5"/>
                    <measurement group_id="O2" value="64.7" lower_limit="56.5" upper_limit="72.1"/>
                    <measurement group_id="O3" value="70.4" lower_limit="58.2" upper_limit="80.4"/>
                    <measurement group_id="O4" value="63.9" lower_limit="51.7" upper_limit="74.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 128</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.5" lower_limit="61.1" upper_limit="76.8"/>
                    <measurement group_id="O2" value="69.9" lower_limit="61.9" upper_limit="76.8"/>
                    <measurement group_id="O3" value="75.4" lower_limit="63.3" upper_limit="84.6"/>
                    <measurement group_id="O4" value="68.6" lower_limit="56.2" upper_limit="78.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 140</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.9" lower_limit="64.6" upper_limit="79.9"/>
                    <measurement group_id="O2" value="66.0" lower_limit="57.8" upper_limit="73.4"/>
                    <measurement group_id="O3" value="75.0" lower_limit="63.2" upper_limit="84.1"/>
                    <measurement group_id="O4" value="65.3" lower_limit="53.1" upper_limit="75.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.4" lower_limit="54.8" upper_limit="71.2"/>
                    <measurement group_id="O2" value="67.9" lower_limit="59.9" upper_limit="75.1"/>
                    <measurement group_id="O3" value="61.6" lower_limit="49.5" upper_limit="72.6"/>
                    <measurement group_id="O4" value="58.9" lower_limit="46.8" upper_limit="70.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.2" lower_limit="62.8" upper_limit="78.4"/>
                    <measurement group_id="O2" value="70.1" lower_limit="61.6" upper_limit="77.4"/>
                    <measurement group_id="O3" value="65.7" lower_limit="53.0" upper_limit="76.6"/>
                    <measurement group_id="O4" value="68.8" lower_limit="55.8" upper_limit="79.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 208</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.7" lower_limit="63.3" upper_limit="78.9"/>
                    <measurement group_id="O2" value="65.8" lower_limit="57.4" upper_limit="73.3"/>
                    <measurement group_id="O3" value="67.2" lower_limit="54.5" upper_limit="77.9"/>
                    <measurement group_id="O4" value="71.2" lower_limit="58.6" upper_limit="81.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 232</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.2" lower_limit="66.7" upper_limit="82.2"/>
                    <measurement group_id="O2" value="73.5" lower_limit="65.0" upper_limit="80.6"/>
                    <measurement group_id="O3" value="79.4" lower_limit="67.0" upper_limit="88.1"/>
                    <measurement group_id="O4" value="84.7" lower_limit="72.5" upper_limit="92.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 260</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.4" lower_limit="65.8" upper_limit="81.5"/>
                    <measurement group_id="O2" value="75.0" lower_limit="66.6" upper_limit="81.9"/>
                    <measurement group_id="O3" value="76.9" lower_limit="64.5" upper_limit="86.1"/>
                    <measurement group_id="O4" value="77.4" lower_limit="64.7" upper_limit="86.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Achieving Disease Remission (DAS28&lt;2.6)</title>
        <description>Percentage of subjects achieving disease remission (DAS28&lt;2.6). The DAS28 is a measure of disease activity in PsA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient's Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission</description>
        <time_frame>weeks 116, 128, 140, 156, 180, 208, 232 and 260</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 75mg</title>
            <description>Subjects initially continued to receive secukinumab 75mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150mg</title>
            <description>Subjects continued to receive secukinumab 150mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 300 mg as judged appropriate by the investigator</description>
          </group>
          <group group_id="O3">
            <title>Placebo - AIN457A 75mg</title>
            <description>Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 1.0 mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 75mg. Participants also received secukinumab 75mg from week 16/24. Patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator</description>
          </group>
          <group group_id="O4">
            <title>Placebo - AIN457 150mg</title>
            <description>Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 0.5mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 150 mg. Participants also received secukinumab 150 mg from week 16/24. patients may have been escalated to 300mg or 300 mg as judged appropriate by investigator</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving Disease Remission (DAS28&lt;2.6)</title>
          <description>Percentage of subjects achieving disease remission (DAS28&lt;2.6). The DAS28 is a measure of disease activity in PsA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient's Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="161"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 116</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4" lower_limit="44.0" upper_limit="60.7"/>
                    <measurement group_id="O2" value="50.3" lower_limit="42.2" upper_limit="58.5"/>
                    <measurement group_id="O3" value="47.9" lower_limit="36.0" upper_limit="60.0"/>
                    <measurement group_id="O4" value="45.8" lower_limit="34.2" upper_limit="57.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 128</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.6" lower_limit="46.0" upper_limit="62.9"/>
                    <measurement group_id="O2" value="49.4" lower_limit="41.3" upper_limit="57.4"/>
                    <measurement group_id="O3" value="55.1" lower_limit="42.7" upper_limit="66.9"/>
                    <measurement group_id="O4" value="57.1" lower_limit="44.8" upper_limit="68.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 140</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6" lower_limit="49.9" upper_limit="66.7"/>
                    <measurement group_id="O2" value="46.7" lower_limit="38.5" upper_limit="55.0"/>
                    <measurement group_id="O3" value="55.6" lower_limit="43.4" upper_limit="67.1"/>
                    <measurement group_id="O4" value="51.4" lower_limit="39.4" upper_limit="63.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.6" lower_limit="40.2" upper_limit="57.1"/>
                    <measurement group_id="O2" value="52.6" lower_limit="44.4" upper_limit="60.6"/>
                    <measurement group_id="O3" value="43.8" lower_limit="32.4" upper_limit="55.9"/>
                    <measurement group_id="O4" value="46.6" lower_limit="35.0" upper_limit="58.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.7" lower_limit="46.0" upper_limit="63.1"/>
                    <measurement group_id="O2" value="53.3" lower_limit="44.6" upper_limit="61.8"/>
                    <measurement group_id="O3" value="49.3" lower_limit="37.0" upper_limit="61.6"/>
                    <measurement group_id="O4" value="58.6" lower_limit="46.2" upper_limit="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 208</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.5" lower_limit="47.8" upper_limit="64.8"/>
                    <measurement group_id="O2" value="52.1" lower_limit="43.7" upper_limit="60.3"/>
                    <measurement group_id="O3" value="55.2" lower_limit="42.6" upper_limit="67.2"/>
                    <measurement group_id="O4" value="53.0" lower_limit="40.4" upper_limit="65.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 232</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.3" lower_limit="55.4" upper_limit="72.4"/>
                    <measurement group_id="O2" value="61.4" lower_limit="52.5" upper_limit="69.6"/>
                    <measurement group_id="O3" value="65.1" lower_limit="51.9" upper_limit="76.4"/>
                    <measurement group_id="O4" value="69.5" lower_limit="56.0" upper_limit="80.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 260</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0" lower_limit="46.0" upper_limit="63.7"/>
                    <measurement group_id="O2" value="58.3" lower_limit="49.4" upper_limit="66.7"/>
                    <measurement group_id="O3" value="64.6" lower_limit="51.7" upper_limit="75.8"/>
                    <measurement group_id="O4" value="66.1" lower_limit="52.9" upper_limit="77.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>week 260</time_frame>
      <desc>Safety analysis is based on the actual dose received. Pts who escalated from 75mg to 150mg or 300mg are also analyzed at the escalated dose Any AIN75: 202 AIN75 + 93 PBO-AIN150 - 3 PBO-AIN150 (re-randomized but not exposed) = 292 Any AIN150: 202 AIN150 + 94 PBO-AIN150 + 178 Up-titrators from 75mg -1 PBO-AIN150 (re-randomized but not exposed) = 473 Any 300: 165 Up-titrators Placebo: 149 pts entered the extension and were on PBO up to wks 16/24. Also, add 53 PBOs who did not enter the extension</desc>
      <group_list>
        <group group_id="E1">
          <title>Any AIN457 75 mg</title>
          <description>Any AIN457 75 mg</description>
        </group>
        <group group_id="E2">
          <title>Any AIN457 150 mg</title>
          <description>Any AIN457 150 mg</description>
        </group>
        <group group_id="E3">
          <title>Any AIN457 300 mg</title>
          <description>Any AIN457 300 mg</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Normocytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Basedow's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular myasthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Femoral hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Obstructive pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Chronic hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Appendiceal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Prostatitis Escherichia coli</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Salpingo-oophoritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Streptococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Typhoid fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Eyelid injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Periprosthetic osteolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Traumatic liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Limb asymmetry</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Intraductal papilloma of breast</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Invasive breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer stage 0</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Leiomyosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Ovarian germ cell teratoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Phaeochromocytoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pleomorphic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Schwannoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of pharynx</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Intracranial venous sinus thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Thrombotic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Adnexa uteri cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pelvic adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pulmonary alveolar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema nodosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Rosacea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pelvic venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Polyarteritis nodosa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="197" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="264" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="63" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="473"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Observed data is reported for outcome measures
The non-fatal adverse events are reported under &quot;Serious Adverse Events&quot;</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clinical Disclosure Office</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>+1 (862) 778-8300</phone>
      <email>novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

